Session: Building Research and Development Capacity to combat neglected tropical diseases 17th November 2023

Introduction to GSK Global Health and the Tres Cantos Open Lab



Félix Calderón Global Health Medicines R&D

Global Health is a cornerstone of our ESG agenda

Global Health is one of the areas of responsible business that matter most to us

Our purpose is to unite science, technology and talent to get ahead of disease together



Photo: GSK. Mbagathi Clinic

GSK

Why we are committed to Global Health

We will change the trajectory of high burden diseases in lower-income countries with a focus on infectious diseases



Photo: GSK. Ratna, LF Patient, Nepal



How we will change the trajectory

Our 3-pronged approach

01

Global Health R&D

Developing new medicines & vaccines against high burden diseases in lower-income countries with a focus on infectious diseases

02

Access

Pursuing equitable access to **GSK's portfolio & pipeline**

03

Health System Strengthening

Build partnerships to strengthen health systems and ensure our innovation reaches **patients who need it most**

GSK GLOBAL HEALTH TEAM

Dedicated team of more than **200 outstanding people** and **two research centres** in Siena, Italy and Tres cantos, Spain



Photo: GSK. Mbagathi Clinic Nairobi



How we will change the trajectory Our commitment to Global Health R&D

GSK is investing **£1bn over ten years** to accelerate Global Health R&D



prevent and treat TB, malaria, AMR, HIV*, enteric diseases & NTDs



* Through ViiV



Photo: GSK. Tres Cantos


The Tres Cantos Open Lab

- A unique collaborative science-driven model to support research in endemic infectious diseases
- Integrated within the GSK R&D site in Tres Cantos (Madrid, Spain)
- Why?
- What
- How



GSK

The What? Addressing the innovation gap



- On therapeutics areas affecting HIC, the innovation gap is partially fill with Biotechs, spin-offs, etc
- Few oppotunities to develop innovation for endemic infectious diseases

GSK

The how? Overcoming 'structural' barriers

A collaborative project-based environment integrating academic and GSK teams

The distinguish features:

55X

- 1. Co-location of scientists from both sectors in the same laboratory
- 2. The greater sharing of intellectual property

3. In partnership with the Tres Cantos Open Lab Foundation (TCOLF) – provides funds and expertise

FOUND IN TRANSLATION

Surmounting structural barriers to tackle endemic infectious diseases

Felix Calderón¹, Alan H. Fairlamb², Mike Strange⁴, Pauline Williams⁴, and Carl F. Nathan³

NATURE DRUG REVIEWS DISCOVERY

Tres Cantos Open Lab: celebrating a decade of innovation in collaboration to combat endemic infectious diseases

Felix Calderón¹¹²⁸, Lluis Ballell¹, David Barros¹, Graeme Bilbe², Nicholas Cammack³, Raquel Gabarró¹, Audra Halsey⁴, Penny M. Heaton⁵, Cagandeep Kang⁶, Valerie Mizrahi⁷, Carl Nathan⁸, Mike E. Strange⁹, Pauline M. Williams⁹, Elizabeth A. Winzeler¹⁰ and Alan H. Fairlamb¹¹¹²⁹

Figure adapted from Calderon, F. *et al.* J Exp Med (**2022**) 218(9):e202114187 Calderon, F. *et al.* Nat Rev Drug Discov (**2022**), 20, 799-800


8

Sa IEM Baperimer

Impact in NTDs / areas of sucess

- Enabling discovery research by generation and publications of:
 - High-quality public datasets
 - Lead compounds with in vivo activity to accelerate community discovery
 - Novel physiologically relevant assays
 - Critical role in the identification of novel clinical candidates

New Compound Sets Identified from High Throughput Phenotypic Screening Against Three Kinetoplastid Parasites: An Open Resource



STUDY PROTOCOL

Open Access

Comparison of 8 weeks standard treatment (rifampicin plus clarithromycin) vs. 4 weeks standard plus amoxicillin/clavulanate treatment [RC8 vs. RCA4] to shorten Buruli ulcer disease therapy (the BLMs4BU trial): study protocol for a randomized controlled multi-centre trial in Benin

Catalyzing clinical research

Figures adapted from Peña, I. *et al.* Sci Reports (**2015**) 5:8771 Johnson, R. C. *et al.* Trials (**2022**) 23:559 https://dndi.org/research-development/portfolio/dndi-6174/

REP



Thank you for your attention

⊕ gsk.com